Abstract: In an example, a request is received from a first user equipment (UE). The request corresponds to a request to establish a communication session with a second UE. A location of the first UE is determined based upon the request. An event datastore is analyzed, based upon the location of the first UE, to identify one or more events potentially impacting telecommunication services provided to the first UE. Based upon the one or more events, an announcement is provided for presentation on the first UE.

Abstract: In one aspect, the present disclosure provides compounds which inhibit bromodomain testis (BRDT). In some embodiments, the compounds inhibit bromodomain-2 of BRDT. In another aspect, the present disclosure provides a method of inhibiting BRDT in a male subject, the method comprising administering to the male subject a therapeutically effective amount of a compound of the disclosure. In some embodiments, the method provides a contraceptive effect in the male subject.

Abstract: Systems and methods permit or cause content to be displayed by a plurality of gaming displays, such as gaming machine displays and/or external displays. Content may be synchronously displayed by multiple gaming displays, such as one or more EGM displays and one or more external gaming displays, where the content which is displayed by the different displays may be the same or be different, and may be provided by a content controller and/or may be provided or triggered by a gaming machine. The systems and methods permit or cause content to be synchronously displayed across multiple gaming displays, such as in time and/or space. In some examples, the content is configured as a content “package” which is associated with one or more displays.

Abstract: An example method includes, outputting, for display by a display device, a graphical user interface of an application executing at a computing device; responsive to receiving an indication of a start of a user input swipe gesture: outputting, for display by the display device and at least partially concealed by the scaled version of the graphical user interface of the application, a visual indication of a result of the user input swipe gesture: and responsive to receiving an indication of a commitment of the user input swipe gesture, outputting, for display by the display device, a graphical user interface that corresponds to the result of the user input swipe gesture.

Abstract: Provided herein are an ?2-3 disialylated PSA protein standard and an ?2-6 disialylated PSA protein standard, as well as various methods for measuring the relative (fractional) amount of the total N-acetylneuraminic acid (Neu5Ac) that is ?2-3-linked N-acetylneuraminic acid (?2-3-linked Neu5Ac) and is ?2-6-linked N-acetylneuraminic acid (?2-6-linked Neu5Ac) on PSA present in a blood serum or plasma sample, which is useful for determining whether a subject has a low risk (GG1), intermediate risk (GG2) or a high risk (GG3, 4 or 5) prostate cancer and/or determining and/or treating whether a human subject suspected of having prostate cancer should receive a needle biopsy. Also included are methods of monitoring and treating a prostate cancer patient post prostate cancer removal surgery for need of additional cancer treatment.

Abstract: Multilayer films comprising polyolefins and products comprising the multilayer films are disclosed. These multilayer films have fewer defects, especially optical defects.

Abstract: A method of manufacturing a preform, the method including positioning at least one glass tube in a glass outer cladding to form a preform precursor, the glass tube comprising a first open end and a second open end, forming a preform from the preform precursor, and thermally treating at least one of the preform precursor and the preform. The thermally treating including sealing the first open end and the second open end of the glass tube to form a closed tube and heating and/or cooling the glass tube to manipulate gas pressure within the closed glass tube.

Abstract: This application describes provisioning a secondary electronic subscriber identity module (eSIM) to a wireless device to access a cellular wireless network of a mobile virtual network operator (MVNO) to supplement and offload from a cellular wireless network of a mobile network operator (MNO) that provides cellular wireless services to users of the MVNO. Provisioning of the secondary eSIM can be triggered after i) boot up of the wireless device or ii) insertion of a primary SIM/eSIM that provides MVNO cellular service access via the MNO cellular wireless network. Provisioning can be anchored by an MVNO entitlement server or by a manufacturer device services server. Provisioning can also be triggered by the MNO cellular wireless network after attachment of the wireless device. Authentication and authorization of the wireless device to obtain the secondary eSIM can be based on the primary SIM/eSIM or on secure communication with the manufacturer device services server.

Abstract: Magnetoelectric magnetic tunnel junction (MEMTJ) logic devices comprise a magnetoelectric switching capacitor coupled to a pair of magnetic tunnel junctions (MTJs) by a conductive layer. The logic state of the MEMTJ is represented by the magnetization orientation of the ferromagnetic layer of the magnetoelectric capacitor, which can be switched through the application of an appropriate input voltage to the MEMTJ. The magnetization orientation of the magnetoelectric capacitor ferromagnetic layer is read out by the MTJs. The conductive layer is positioned between the capacitor and the MTJs. The MTJ ferromagnetic free layers are exchange coupled to the ferromagnetic layer of the magnetoelectric capacitor. The potential of an MTJ free layer is based on a supply voltage applied to the reference layer of the MTJ. The MTJ reference layers have a magnetization orientation that is parallel or antiparallel to the magnetization orientations of the ferromagnetic layer of the magnetoelectric capacitor.

Abstract: In some embodiments, an affixed group of pharmaceutical vials with frangible connectors includes: a plurality of pharmaceutical vials arranged as a group of pharmaceutical vials, each of the plurality of pharmaceutical vials shaped and positioned to minimize a total volume of the group of pharmaceutical vials, each of the pharmaceutical vials including at least one external side with a surface configured to reversibly mate with a corresponding external side and a surface of an adjacent pharmaceutical vial; and a plurality of frangible connectors, wherein at least one frangible connector is affixed to the surface of at least two of the plurality of pharmaceutical vials within the group of pharmaceutical vials, and at least one frangible connector is affixed to each of the plurality of pharmaceutical vials.

Abstract: A method for controlling a near eye display system, includes obtaining an eye movement of a user wearing the near eye display system using an eye tracking sensor of the near eye display system, determining a target area of a display of the near eye display system based on the eye movement of the user, the target area of the display being an area that the user is looking at, and controlling a brightness of the target area of the display of the near eye display system to cause a size of a pupil of the user to be in a predetermined range.

Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.

Abstract: A memory controller comprises a command interface to transmit a memory command to a plurality of memory devices associated with the memory controller. The memory controller also comprises an acknowledgement interface to receive an acknowledgment status packet from the plurality of memory devices over a shared acknowledgement link coupled between the memory controller and the plurality of memory devices, the acknowledgement status packet indicating whether the command was received by the plurality of memory devices. In addition, the memory controller comprises a memory controller core to decode the acknowledgment status packet to identify a portion of the acknowledgement status packet corresponding to each of the plurality of memory devices.

Abstract: Described herein are systems and methods that search videos and other media content to identify items, objects, faces, or other entities within the media content. Detectors identify objects within media content by, for instance, detecting a predetermined set of visual features corresponding to the objects. Detectors configured to identify an object can be trained using a machine learned model (e.g., a convolutional neural network) as applied to a set of example media content items that include the object. The systems comprise an integrated detection unit configured to record media content, identify preferred content, and communicate the identifications of preferred content for storage in a computationally efficient manner.

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Abstract: A system for mask design repair may develop a simulation-based model of a layer thickness after one or more process steps for fabricating features on a sample, develop a transformed model of the fabrication process that emulates the simulation-based model and has a faster evaluation speed than the simulation-based model, and where the inputs to the transformed model include the input mask design, and where the outputs of the transformed model include one or more output parameters associated with fabrication of the input mask design as well as one or more sensitivity metrics describing sensitivities of the one or more output parameters to variations of the input mask design. The system may further receive a candidate mask design and generate a repaired mask design based on the transformed model and the candidate mask design.

Abstract: Aspects of the present disclosure relate to the sharing of synchronization information corresponding to content among devices in a communication network. An originating device collects synchronization information related to the presentation of content to a user via the originating device. The synchronization information is defined according to reference points related to the presentation of the content to the user via the originating device, including a current state of the presentation of the content and/or additional information obtained during the presentation of the content. Based on detection of a synchronization event, the originating device transmits the collected synchronization information, resulting in the receipt of the synchronization information by one or more receiving devices. Thereafter, the presentation of the content to the user on one of the receiving devices can incorporate the synchronization information collected and transmitted by the originating device.

Abstract: Systems and methods for training models to improve fairness.

Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.